eNewsroom for: Genelux

http://pressreleaseheadlines.com/wp-content/Cimy_User_Extra_Fields/Genelux/Screen-Shot-2013-11-18-at-8.23.12-AM.png

Genelux Company Profile

Headquartered in San Diego, California, Genelux Corporation is a privately held, clinical stage biopharmaceutical company dedicated to fundamentally changing the way in which cancer is diagnosed and treated. The company has developed a proprietary oncolytic vaccinia virus-based technology platform that can be engineered to insert specific diagnostic and/or therapeutic genes for delivery and amplification in cancer cells without harming healthy cells. This platform includes a green fluorescent protein (GFP) as a bioluminescent diagnostic. The company is also incorporating advanced diagnostic deep-tissue imaging technologies into its viral platform to enable highly specific visualization of tumors and circulating cancer cells. GL-ONC1, the company’s lead product candidate, is an attenuated vaccinia virus (Lister strain) that is currently under evaluation in multiple human clinical trials in the US and Europe.

News from Genelux:

Genelux, a Leader in the Emerging Oncolytic Virotherapy Field, Receives Significant Industry Honor from Elsevier Business Intelligence, Identifying GL-ONC1 as One of 2013's 'Top Oncology Projects to Watch'

Recognition marks significant industry honor for Genelux proprietary vaccinia-based platform technology
SAN DIEGO, Nov. 18, 2013 /PRNewswire/ – Genelux Corporation, a leader in the emerging field of oncolytic virotherapy, announced today that the Company's lead product candid…